Comparative efficacy and safety of PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is the most prevalent histological subtype of lung cancer globally and remains a leading cause of cancer-related mortality. The advent of programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors has markedly transformed advanced NSCLC treatment, providing patients with broader access to individualized treatment strategies. This study aims to systematically examine the efficacy and safety of PD-1/PD-L1 inhibitors in treating NSCLC in comparison to docetaxel.

Methods

PubMed, Embase, Cochrane, and Web of Science were thoroughly retrieved from inception to 2024. Data on overall survival (OS), progression-free survival (PFS) with 95% confidence intervals (CIs), pooled hazard ratios (HRs), duration of respon

SUBMITTER: Liao S 

PROVIDER: S-EPMC12603480 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature